Thermo Fisher Scientific Bioproduction Brochures

  1. How Can You Actively Reduce Particulate Burden In Your Workflow? 8/4/2026

    Particulate control starts with practical decisions. Learn how material selection, acceptance criteria, and operator handling practices can help reduce contamination risk and support stronger quality.

  2. Nalgene Low And Ultralow Particulate Containers 8/4/2026

    Choose the right level of clean for bioproduction storage and transport, with options designed to help manage particulate, endotoxin, sterility and material requirements across critical workflows.

  3. Enabling Flexibility For T Cell Isolation And Activation Using Workflows 7/16/2026

    Modular manufacturing strategies can support scalable T-cell processing while maintaining key quality measures. Explore how workflow design choices can help balance efficiency and performance.

  4. From Process Development To QC—Optimize Your mAbs Workflow 5/29/2026

    See how integrated analytical capabilities help improve visibility across mAb workflows, enabling faster decisions, stronger process control, and reliable quality outcomes from development through QC.

  5. Leading The Way In Rapid Quantitation Of Host Cell DNA 5/29/2026

    Accurate, high-sensitivity quantitation of residual host cell DNA becomes faster and more consistent with integrated qPCR, automated prep, and broad assay coverage—helping streamline workflows.

  6. Advancing Cell Therapy With The CTS DynaCellect Magnetic Separation System 4/21/2026

    Closed, automated T cell isolation with greater than 85% efficiency and greater than 96% purity is now achievable in 70 to 100 minutes, with cGMP-ready scalability from research to clinical manufacturing.

  7. Cell Therapy: T Cell Isolation From Whole Blood 4/21/2026

    Whole blood offers a faster, lower-cost starting material for T cell isolation and CTS Detachable Dynabeads CD4/CD8 with the DynaCellect System make it a viable, cGMP-aligned option without preprocessing.

  8. Cell Therapy Selection Guide: Connected From Activation To Expansion 4/21/2026

    Active bead release gives manufacturers precise control over T cell isolation timing, phenotype preservation, and workflow efficiency, eliminating multi-day passive dissociation delays.

  9. Integrated T Cell Activation: Soluble DynActivator CD3/CD28 Prototype 4/21/2026

    Bead-free T cell activation is now achievable with a soluble, GMP-compliant format that supports up to 1.5 billion cells per vial, decouples activation from isolation, and removes with a simple cell wash.

  10. Dynabeads CD3 Depletion Prototype Supporting Solutions From Development To Delivery 4/21/2026

    Residual CD3+ cells shouldn't be the bottleneck in your allogeneic therapy workflow. This prototype achieves <0.5% residual T cells at commercial-scale processing capacity.